Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 15/20 | 0.48 |
| ▸ | JAK1 | P23458 | 15/20 | 0.48 |
| ▸ | TYK2 | P29597 | 15/20 | 0.48 |
| ▸ | JAK3 | P52333 | 15/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19436552 | 0.83 | PTGER4 (0.56) | PTGER4KMT2AJAK2JAK1TYK2 | |
| Bromide SCHEMBL29619880 | 0.82 | PTGER4 (0.55) | PTGER4KMT2AJAK2JAK1TYK2 | |
| Bromide SCHEMBL28608182 | 0.82 | PTGER4 (0.55) | PTGER4KMT2AJAK2JAK1TYK2 | |
| SCHEMBL19436565 | 0.82 | PTGER4 (0.55) | PTGER4KMT2AJAK2JAK1TYK2 | |
| SCHEMBL19448908 | 0.79 | PTGER4 (0.55) | PTGER4KMT2AJAK2JAK1TYK2 | |
| SCHEMBL22121416 | 0.72 | KMT2A (0.57) | KMT2AJAK2JAK1TYK2JAK3 | |
| SCHEMBL22121361 | 0.70 | KMT2A (0.54) | KMT2AJAK2JAK1TYK2JAK3 | |
| SCHEMBL15774442 | 0.70 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL21648038 | 0.69 | NPC1 (0.57) | PTGER4KMT2A | |
| SCHEMBL24467554 | 0.69 | PTGER4 (0.48) | PTGER4KMT2AJAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365190-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-06-21 | — | — | US | disclosed |
| US-20210139473-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365190-B2 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | PTGER4 3619/4885KMT2A 1428/4885JAK2 2724/4885 |
| US-20210139473-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | RB1, RBBP5, RCC2 | PTGER4 3619/4885KMT2A 1428/4885JAK2 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.